Data showed overall vaccine efficacy against RSV-lower respiratory tract disease in adults aged 60 years and above| www.gsk.com
Respiratory syncytial virus (RSV) hospitalizes over 50,000 Americans each year. Two physicians information on which preventive steps to take.| American Medical Association
The surge in RSV cases following the COVID-19 pandemic may have been, in part, caused by increased testing and changes to the RSV genome, according to a Northwestern Medicine study published in Nature Communications.| News Center
Thought only to infect the respiratory tract, new research has proved for the first time that the respiratory syncytial virus (RSV), very common in young children, can also penetrate nerve cells directly, triggering excessive inflammation and potentially leading to nerve damage. The findings…| New Atlas
Biotechnology company Moderna has announced promising results from its massive Phase 3 trial testing an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. The data indicates the vaccine is nearly 84% effective at preventing moderate disease and the company expects to file for US…| New Atlas
After decades of research a long-awaited vaccine against respiratory syncytial virus (RSV) may finally be here. Preliminary Phase 3 data has revealed maternal immunization with a new vaccine delivered extraordinary protection from severe disease in babies across their first few months of life.| New Atlas
